R R

What Is Rituxan Hycela?

Rituxan Hycela is a prescription biologic medication containing rituximab and hyaluronidase human. Rituximab targets CD20-positive B cells, while hyaluronidase temporarily increases tissue permeability to permit administration beneath the skin. Rituxan Hycela is approved for selected adults with follicular lymphoma, diffuse large B-cell lymphoma, or chronic lymphocytic leukemia. It is administered by a healthcare professional as an injection into the abdomen rather than an intravenous infusion. Patients must first receive at least one full dose of an intravenous rituximab product before starting Rituxan Hycela. The medication carries boxed warnings for serious infusion or administration reactions, severe skin reactions, hepatitis B reactivation, and progressive multifocal leukoencephalopathy.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Rituxan Hycela?

Rituxan Hycela is a prescription biologic medication containing rituximab and hyaluronidase human. Rituximab targets CD20-positive B cells, while hyaluronidase temporarily increases tissue permeability to permit administration beneath the skin. Rituxan Hycela is approved for selected adults with follicular lymphoma, diffuse large B-cell lymphoma, or chronic lymphocytic leukemia. It is administered by a healthcare professional as an injection into the abdomen rather than an intravenous infusion. Patients must first receive at least one full dose of an intravenous rituximab product before starting Rituxan Hycela. The medication carries boxed warnings for serious infusion or administration reactions, severe skin reactions, hepatitis B reactivation, and progressive multifocal leukoencephalopathy.

read more about rituxan hycela ...

Copy this HTML:

Copy HTML Copied!

How Does Rituxan Hycela Work?

Rituxan Hycela combines two ingredients with different functions. Rituximab binds to the CD20 protein on B lymphocytes, triggering immune mechanisms that destroy certain normal and malignant B cells. This helps reduce the number of cancerous B cells in selected lymphomas and chronic lymphocytic leukemia. Hyaluronidase human temporarily breaks down hyaluronan in connective tissue, improving the dispersion and absorption of rituximab after subcutaneous injection. The enzyme supports drug delivery rather than acting directly against cancer cells. Rituxan Hycela can suppress B-cell activity for an extended period, increasing the risk of serious infections.

What Cancers Does Rituxan Hycela Treat?

Rituxan Hycela is approved for adults with selected types of follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. For follicular lymphoma, it may be used alone or with chemotherapy in specified previously treated or previously untreated settings, including maintenance treatment when appropriate. For diffuse large B-cell lymphoma, it is used with CHOP or another approved anthracycline-based chemotherapy regimen in previously untreated patients. For chronic lymphocytic leukemia, it is used with fludarabine and cyclophosphamide. Rituxan Hycela is not approved for rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, or pemphigus vulgaris. It is not indicated for pediatric patients.

How Is Rituxan Hycela Administered?

Rituxan Hycela is administered by a healthcare professional as a subcutaneous injection into the abdomen. Before the first subcutaneous dose, patients must receive and tolerate at least one full dose of an intravenous rituximab product. For follicular lymphoma and diffuse large B-cell lymphoma, the fixed dose contains 1,400 mg of rituximab and 23,400 units of hyaluronidase human, injected over approximately five minutes. For chronic lymphocytic leukemia, the dose contains 1,600 mg of rituximab and 26,800 units of hyaluronidase, injected over approximately seven minutes. Patients receive appropriate premedication and are monitored for at least 15 minutes after administration. Treatment schedules depend on the cancer and chemotherapy regimen.

What Are the Side Effects and Warnings of Rituxan Hycela?

Common adverse effects include injection-site redness, pain, swelling, fever, fatigue, nausea, and infections. Rituxan Hycela carries boxed warnings for potentially fatal administration-related reactions, severe skin and mucosal reactions, hepatitis B reactivation, and progressive multifocal leukoencephalopathy. Serious risks also include low blood cell counts, tumor lysis syndrome, severe infections, heart complications, and embryo-fetal harm. Hepatitis B screening is required before treatment, and patients must be monitored for adverse reactions. Facial swelling, breathing difficulties, chest pain, widespread blistering, or new neurological symptoms requires immediate medical assessment.

Common Questions About Rituxan Hycela

Is Rituxan Hycela the same as Rituxan?

Both contain rituximab, but Rituxan Hycela also contains hyaluronidase human and is administered beneath the skin. Their approved indications and administration procedures differ.

Why is intravenous rituximab required before Rituxan Hycela?

Patients must receive at least one full intravenous rituximab dose before switching because serious administration reactions are more likely during initial exposure.

Where is Rituxan Hycela injected?

Rituxan Hycela is injected into the subcutaneous tissue of the abdomen by a healthcare professional. It is not administered intravenously.

Can Rituxan Hycela treat rheumatoid arthritis?

No. Rituxan Hycela is approved for selected adult blood cancers, not rheumatoid arthritis or the other autoimmune indications of intravenous Rituxan.

References

DailyMed - RITUXAN HYCELA (rituximab and hyaluronidase human) injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e5b7e82-f018-4eaf-ae78-d6145a906b20. Date Accessed November 4, 2026.

Rituxan Hycela - Information for Healthcare Providers. Genentech. https://www.gene.com/medical-professionals/medicines/rituxan-hycela. Date Accessed November 4, 2026.

Rituximab and Hyaluronidase Human. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/rituximabandhyaluronidasehuman. Date Accessed November 4, 2026.

Rituximab and Hyaluronidase Human Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a619047.html. Date Accessed November 4, 2026.

RITUXAN HYCELA Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761064s008s010lbl.pdf. Date Accessed November 4, 2026.